CORCEPT THERAPEUTICS INC (CORT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 300M 600M 900M FY09: 29K FY16: 81.3M FY17: 159.2M FY18: 251.2M FY19: 306.5M FY20: 353.9M FY21: 366M FY22: 401.9M FY23: 482.4M FY24: 675M FY25: 761.4M FY09 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 300M 600M 900M FY16: 79.3M FY17: 155.6M FY18: 246M FY19: 301M FY20: 348.3M FY21: 360.7M FY22: 396.5M FY23: 475.9M FY24: 664.2M FY25: 748.4M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-50M 0 50M 100M 150M FY09: -20.2M FY10: -27.4M FY11: -32.3M FY12: -36.3M FY13: -41.5M FY14: -27.6M FY15: -3.4M FY16: 10.2M FY17: 52.9M FY18: 89.5M FY19: 111.6M FY20: 128.2M FY21: 124.5M FY22: 112.6M FY23: 107.3M FY24: 137M FY25: 44.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-50M 0 50M 100M 150M FY00: -1.8M FY01: -7.5M FY02: -18.5M FY03: -9.8M FY04: -15.5M FY05: -20.1M FY06: -24.9M FY07: -11.6M FY08: -20.1M FY09: -20.2M FY10: -26M FY11: -32.4M FY12: -38M FY13: -46M FY14: -31.4M FY15: -6.4M FY16: 8.1M FY17: 129.1M FY18: 75.4M FY19: 94.2M FY20: 106M FY21: 112.5M FY22: 101.4M FY23: 106.1M FY24: 141.2M FY25: 99.7M FY01 FY04 FY07 FY10 FY13 FY16 FY19 FY22 FY25

Cost of Revenue Annual

0 5M 10M 15M FY12: 91K FY13: 143K FY14: 882K FY15: 1.4M FY16: 2.1M FY17: 3.6M FY18: 5.2M FY19: 5.5M FY20: 5.6M FY21: 5.3M FY22: 5.4M FY23: 6.5M FY24: 10.9M FY25: 13M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-70M 0 70M 140M 210M FY09: -18M FY10: -22.3M FY11: -27.4M FY12: -36M FY13: -37.1M FY14: -27.4M FY15: 3.1M FY16: 18.4M FY17: 60.9M FY18: 115.7M FY19: 136.1M FY20: 152M FY21: 167.9M FY22: 120.3M FY23: 126.7M FY24: 198.3M FY25: 142M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-70M 0 70M 140M 210M FY11: -27.4M FY12: -36.2M FY13: -37.2M FY14: -27.6M FY15: 3.1M FY16: 18.2M FY17: 60.5M FY18: 115.4M FY19: 135M FY20: 150.7M FY21: 167.4M FY22: 119.9M FY23: 126.5M FY24: 196.1M FY25: 141.8M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 50M 100M 150M FY14: 101M FY15: 106.9M FY16: 116.1M FY17: 124.5M FY18: 126.7M FY19: 122.6M FY20: 124.2M FY21: 126M FY22: 116M FY23: 111.7M FY24: 113.5M FY25: 120M FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.50 0.00 0.50 1.00 1.50 Q4 '10: -0.38 Q1 '11: -0.38 Q2 '11: -0.40 Q3 '11: -0.38 Q4 '11: -0.40 Q1 '12: -0.44 Q1 '13: -0.40 Q2 '13: -0.43 Q3 '13: -0.46 Q4 '13: -0.46 Q1 '14: -0.48 Q2 '14: -0.43 Q3 '14: -0.38 Q4 '14: -0.31 Q1 '15: -0.22 Q2 '15: -0.17 Q3 '15: -0.12 Q4 '15: -0.07 Q1 '16: -0.02 Q2 '16: 0.01 Q3 '16: 0.04 Q4 '16: 0.07 Q1 '17: 0.11 Q2 '17: 0.20 Q3 '17: 0.29 Q4 '17: 1.02 Q1 '18: 1.12 Q2 '18: 1.16 Q3 '18: 1.19 Q4 '18: 0.60 Q1 '19: 0.61 Q2 '19: 0.64 Q3 '19: 0.72 Q4 '19: 0.78 Q1 '20: 0.88 Q2 '20: 0.94 Q3 '20: 0.89 Q4 '20: 0.85 Q1 '21: 0.78 Q2 '21: 0.76 Q3 '21: 0.83 Q4 '21: 0.89 Q1 '22: 0.91 Q2 '22: 0.94 Q3 '22: 1.00 Q4 '22: 0.88 Q1 '23: 0.82 Q2 '23: 0.83 Q3 '23: 0.81 Q4 '23: 0.95 Q1 '24: 1.06 Q2 '24: 1.13 Q3 '24: 1.26 Q4 '24: 1.23 Q1 '25: 1.15 Q2 '25: 1.12 Q3 '25: 0.87 Q4 '25: 0.82 Q1 '26: 0.35 Q2 '26: 0.42 Q3 '11 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.